Ramy Ibrahim Net Worth

Ramy Ibrahim biography

Dr. Ramy Ibrahim serves as Independent Director of the Company. He has served as Chief Medical Officer and Vice President of Clinical Development at the Parker Institute for Cancer immunotherapy since July 2016. Dr. Ibrahim previously served from February 2014 to July 2016 as the Vice President of Clinical Development for immuno-Oncology at AstraZeneca plc, and led the development of the early checkpoint inhibitor antibodies durvalumab (Imfinzi®) and tremelimumab. Dr. Ibrahim also served from April 2011 to February 2014 as the Senior Medical Director of Clinical Development Oncology at Medimmune, LLC. Dr. Ibrahim also served from October 2005 to April 2011 as the Group Director of Oncology Global Clinical Research at Bristol-Myers Squibb Company, where he played a key role in the clinical development of ipilimumab (Yervoy®), the first FDA-approved immune checkpoint inhibitor, from early phase II through multiple global launches. Dr. Ibrahim also played a key role in the early development of nivolumab (Opdivo®), as well as the development of anti-PD-Ll and anti­CDl37 antibody programs. Dr. Ibrahim is actively involved in global cancer immunotherapy networks such as the Society of Immunotherapy for Cancer (SITC), Ludwig Institute, the Cancer Research Institute and the Cancer Immunotherapy Trials Network. Dr. Ibrahim trained in medicine and medical oncology at Cairo University then conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, Maryland. Our Board of Directors believes Dr. Ibrahim’s qualifications to serve as a member of our board include his extensive experience in the pharmaceutical industry.

What is the salary of Ramy Ibrahim?

As the Independent Director of Surface Oncology Inc, the total compensation of Ramy Ibrahim at Surface Oncology Inc is $26,602. There are 11 executives at Surface Oncology Inc getting paid more, with J. Jeffrey Goater having the highest compensation of $1,642,260.

How old is Ramy Ibrahim?

Ramy Ibrahim is 45, he's been the Independent Director of Surface Oncology Inc since 2019. There are 13 older and 1 younger executives at Surface Oncology Inc. The oldest executive at Surface Oncology Inc is Elliott Sigal, 68, who is the Independent Director.

What's Ramy Ibrahim's mailing address?

Ramy's mailing address filed with the SEC is C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE, MA, 02139.

Insiders trading at Surface Oncology Inc

Over the last 7 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.

What does Surface Oncology Inc do?

surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww

Surface Oncology Inc executives and stock owners

Surface Oncology Inc executives and other stock owners filed with the SEC include:

• J. Jeffrey Goater,
  President, Chief Executive Officer, Director
• Vito Palombella,
  Chief Scientific Officer
• Robert Ross,
  Chief Medical Officer
• J. Jeffrey Goater,
  CEO, Pres & Director
• Dr. Robert W. Ross,
  Chief Medical Officer
• Daniel Lynch,
  Executive Chairman of the Board
• Laurie Stelzer,
  Independent Director
• Cameron McDonough,
  Independent Director
• Armen Shanafelt,
  Independent Director
• David Grayzel,
  Independent Director
• Elliott Sigal,
  Independent Director
• Ramy Ibrahim,
  Independent Director
• Liisa Nogelo,
  Chief Legal Officer, Secretary
• Wendy Dwyer,
  Chief Business Officer
• Jessica Fees,
  Principal Financial Officer, Principal Accounting Officer, Senior Vice President, Finance and Treasurer
• Alison O'Neill,
  Sr. VP of Clinical Devel.
• Bob Steininger,
  Sr. VP of Chemistry, Manufacturing & Controls
• Lisa McGrath,
  Sr. VP of HR
• Liisa I. Nogelo,
  Sec., Chief Compliance Officer & Chief Legal Officer
• Jessica Fees,
  Sr. VP of Fin. & Treasurer
• Carsten Brunn,
  Director
• Theresa Boni,
  General Counsel & Secretary
• Enterprise Associates 14, L...,
  
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• Patrick J Kerins,
  10% owner
• Forest Baskett,
  10% owner
• M James Barrett,
  10% owner
• Institutes For Bio Medical ...,
  
• Venture Fund Ix, L.P.Atlas ...,
  
• Management Group, Llc Lilly...,
  
• Peter W. Sonsini,
  10% owner
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 14, L...,
  10% owner
• 2017 Liquidating Trust Kear...,
  
• Llc Fmr,
  
• Ltd Fil,
  
• Geoff Mcdonough,
  Director
• Capital, Llc Eco R1,
  10% owner
• Alison Oneill,
  Chief Medical Officer
• Henry C. Rath,
  Chief Business Officer
• Denice Torres,
  Director
• Benjamin Hickey,
  Director
• Chandra Adams,
  Deputy GC